Medias & investors

LinKinVax has the trust of world-class partners and investors.

A Unique project

They value our long-term prospects and our ability to use our promising biotechnology to become a leading player in a large and strategic market.

They have confidence in LinKinVax’s:

Unique dendritic cell-targeting vaccine platform allowing rapid development of highly versatile and efficient vaccines.
Promising pipeline of vaccines including SARS-CoV-2, HIV and HPV linked Cancer.
Scalable and reliable production model.
Protected patent portfolio.
Strong ties with public scientific and academic institutions.

To deliver efficient vaccines for the two novel viruses discovered each year and:

Participate in preventing 732 000 deaths, 322 million diseases and a 1,3 trillion-dollar loss a year.
Secure Europe’s leading vaccine industry.
Become a major player in the 10,7% annual growth, 47 billion dollars, market of vaccine.

LinKinVax has a binding contract with two major French public research institutions: the French National Institute for Health and Medical Research (Inserm) and the Vaccine Research Institute (VRI).

Since 2011, Inserm funded the VRI for more than 50 million euros from with very encouraging results. Its research program, powering LinKinVax’ science, has an estimated 8-year lead over competing programmes.

LinKinVax benefits from an exclusive intellectual license agreement over the entire patents portfolio of the VRI.

This unique portfolio includes more than one hundred patents covering all stages of dendritic cell vaccine development. Intellectual property is legally protected in France and worldwide.

Unlike many vaccines candidates, LinKinVax’ vaccine platform is based on a reliable technology: the protein vaccine. This type of vaccine has been used for over 30 years with excellent results.

This history guarantees high medical and economic safety. The medical use of proteins and antibodies is well known and documented, which allows LinKinVax to get straight to the point regarding vaccine efficiency and patient safety.

Furthermore, production is reliable thus ensuring predictable quality, volume and price.

LinKinVax’ management team has a proven track record in leading ambitious research projects and building large technology companies.

The two co-founders combine over thirty years of experience at the forefront of the semiconductor industry and medical research.

They have surrounded themselves with people of experience who, for many, participated in the successes of VRI and Soitec. They have an average of 20 years’ experience in their respective fields.

Today, LinKinVax has a particularly complete pipeline with 5 vaccines in market access over the next 5 years, including 3 in clinical trials.

These vaccines cover a wide range of pathogens of global interest, from Sars-CoV-2 to HIV, Chlamydia and HPV-related cancers.

The work of VRI, powering LinKinVax’ science, allows new applications to be considered on a regular basis and the technology enabling the development of these new vaccines is protected by an exclusive intellectual property licensing agreement.

Press Releases

June 21, 2021

Press release

Biotech start-up LinKinvax is created to accelerate the development, clinical trial and market access of a unique and innovative vaccine platform
May 26, 2021

Press release

LinKinVax-Labex VRI consortium secures 31 M€ in public funding to develop a booster vaccine against COVID-19